Boston, MA -- (SBWIRE) -- 09/11/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (ExOne Co (NASDAQ:XONE), CYS Investments Inc(NYSE:CYS), Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR)
ExOne Co (NASDAQ:XONE) shares fell 3.78% to $62.70. The company on Sept. 10 announced that it has priced its previously announced underwritten public offering of 2,656,000 shares of its common stock at a price of $62.00 per share. Of the 2,656,000 shares sold, 1,106,000 shares were sold by ExOne and 1,550,000 were sold by certain selling stockholders. The proceeds to ExOne from the sale of shares are expected to be approximately $64.8 million after deducting the underwriting discounts and commissions and estimated offering expenses. The closing of the offering is expected to take place on September 13, 2013. The underwriters have an option to purchase up to an additional 398,400 shares of common stock from certain selling stockholders.
How Should Investors Trade XONE After The Recent Volatility? Get Free Report Here
CYS Investments Inc(NYSE:CYS) shares climbed 0.13% to $7.76. The Board of Directors of CYS Investments, Inc. on Sept. 9 declared a quarterly dividend of $0.34 per share of common stock for the third quarter of 2013. The common stock dividend will be paid on October 16, 2013 to common stock stockholders of record on September 24, 2013.
In accordance with the terms of the 7.75% Series A Cumulative Redeemable Preferred Stock ("Series A Preferred Stock") of the Company, the Board of Directors of the Company has declared a Series A Preferred Stock cash dividend of $0.484375 per share of Series A Preferred Stock for the quarterly period that began on July 15, 2013, and ends on October 14, 2013. This dividend is payable on October 15, 2013 to Series A Preferred Stock stockholders of record as of October 1, 2013.
How Should Investors Trade CYS After The Recent Volatility? Get Free Report Here
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) shares declined 2.48% to $8.64. Shareholder rights attorneys at Robbins Arroyo LLP on Sept. 5 are investigating the acquisition of Astex Pharmaceuticals, Inc. by Otsuka Pharmaceutical Co., Ltd. ("Otsuka"). On September 5, 2013, the two companies announced the signing of a definitive merger agreement under which Otsuka will acquire Astex for $8.50 per share in cash. The transaction is expected to close in the fourth quarter of 2013.
Additionally, the company, on Sept. 6, announced that management team members will not participate at three banking conferences at which the company had previously planned to present. The three are the Rodman & Renshaw Annual Global Investment Conference, the Morgan Stanley Global Healthcare Conference, and the Stifel Healthcare Conference 2013.
Is ASTX A Good Buy After The Recent Price Movement? Find Out Here
Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) shares declined 5.47% to $5.53. The company on Sept 6 announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules. The settlement agreement grants Wockhardt the right to begin selling a generic version of NUEDEXTA on July 30, 2026, or earlier under certain circumstances.
Is AVNR A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)